SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection.

Abstract

To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for fetal neuroprotection of the preterm infant. Antenatal MgSO4 administration should be considered for fetal neuroprotection when women present at ≤ 31+6 weeks with imminent preterm birth, defined as a high likelihood of birth because of active labour with cervical dilatation ≥ 4 cm, with or without preterm pre-labour rupture of membranes, and/or planned preterm birth for fetal or maternal indications. There are no other known fetal neuroprotective agents. The outcomes measured are the incidence of cerebral palsy (CP) and neonatal death. Published literature was retrieved through searches of PubMed or Medline, CINAHL..